Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 3, 2011, Pages 1046-1051

  Cencic, Regina ^a   Hall, David R ^c   Robert, Francis ^a   Du, Yuhong ^d   Min, Jaeki ^d   Li, Lian ^d   Qui, Min ^d   Lewis, Iestyn ^d   Kurtkaya, Serdar ^d   Dingledine, Ray ^d   Fu, Haian ^d   Kozakov, Dima ^c   Vajda, Sandor ^c   Pelletier, Jerry ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Boston University   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Chemical genetics; eIF4E:eIF4G inhibitor; Lymphoma; Translation inhibitor

Indexed keywords

4E1RCAT; ANTINEOPLASTIC AGENT; DNA; DOXORUBICIN; INITIATION FACTOR; INITIATION FACTOR COMPLEX ELF4F; RAPAMYCIN; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER THERAPY; CHEMORESISTANCE; CONTROLLED STUDY; DNA DAMAGE; DRUG INHIBITION; DRUG MECHANISM; FEMALE; GENETIC ENGINEERING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LYMPHOMA; MOLECULAR MODEL; MOUSE; NONHUMAN; PHYSICAL SENSITIVITY; PRIORITY JOURNAL; SENSITIZATION; TRANSLATION INITIATION; VALIDATION PROCESS;

EUKARYOTA;

EID: 79551648564     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1011477108     Document Type: Article

References (29)

1. Gingras AC, Raught B, Sonenberg N (1999) eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68:913-963.
2. Svitkin YV, et al. (2001) The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5′ secondary structure. RNA 7:382-394.
3. Graff JR, Konicek BW, Carter JH, Marcusson EG (2008) Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68:631-634.
4. Guertin DA, Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2:pe24.
5. Armengol G, et al. (2007) 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 67:7551-7555.
6. Lazaris-Karatzas A, Montine KS, Sonenberg N (1990) Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345:544-547. (Pubitemid 20178912)
7. Wendel HG, et al. (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428:332-337.
8. Rousseau D, Gingras AC, Pause A, Sonenberg N (1996) The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 13:2415-2420. (Pubitemid 27026024)
9. DeFatta RJ, Nathan CA, De Benedetti A (2000) Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope 110:928-933.
10. Herbert TP, Fahraeus R, Prescott A, Lane DP, Proud CG (2000) Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E. Curr Biol 10:793-796. (Pubitemid 30466944)
11. Moerke NJ, et al. (2007) Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128:257-267.
12. Graff JR, et al. (2007) Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 117:2638-2648.
13. Bordeleau ME, et al. (2008) Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 118:2651-2660.
14. Cencic R, et al. (2009) Antitumor activity and mechanism of action of the cyclopenta[b] benzofuran, silvestrol. PLoS ONE 4:e5223.
15. Brenke R, et al. (2009) Fragment-based identification of druggable "hot spots" of proteins using Fourier domain correlation techniques. Bioinformatics 25:621-627.
16. Pestova TV, et al. (2001) Molecular mechanisms of translation initiation in eukaryotes. Proc Natl Acad Sci USA 98:7029-7036.
17. Pestova TV, Hellen CU, Shatsky IN (1996) Canonical eukaryotic initiation factors determine initiation of translation by internal ribosomal entry. Mol Cell Biol 16:6859-6869.
18. Robert F, et al. (2006) Initiation of protein synthesis by hepatitis C virus is refractory to reduced eIF2.GTP.Met-tRNAiMet ternary complex availability. Mol Biol Cell 17:4632-4644.
19. Wendel HG, et al. (2007) Dissecting eIF4E action in tumorigenesis. Genes Dev 21:3232-3237.
20. Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J (2008) c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res 68:5326-5334.
21. Wendel HG, et al. (2006) Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 66:7639-7646.
22. Mills JR, et al. (2008) mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 105:10853-10858.
23. De Gregorio E, Preiss T, Hentze MW (1998) Translational activation of uncapped mRNAs by the central part of human eIF4G is 5′ end-dependent. RNA 4:828-836.
24. Ali IK, McKendrick L, Morley SJ, Jackson RJ (2001) Truncated initiation factor eIF4G lacking an eIF4E binding site can support capped mRNA translation. EMBO J 20:4233-4242.
25. De Gregorio E, Preiss T, Hentze MW(1999) Translation driven by an eIF4G core domain in vivo. EMBO J 18:4865-4874.
26. Pestova TV, Kolupaeva VG (2002) The roles of individual eukaryotic translation initiation factors in ribosomal scanning and initiation codon selection. Genes Dev 16:2906-2922.
27. Gunnery S, Maivali U, Mathews MB (1997) Translation of an uncapped mRNA involves scanning. J Biol Chem 272:21642-21646.
28. Novac O, Guenier AS, Pelletier J (2004) Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen. Nucleic Acids Res 32:902-915.
29. Edery I, et al. (1983) Involvement of eukaryotic initiation factor 4A in the cap recognition process. J Biol Chem 258:11398-11403.